Is Neurotensin legal in Australia?

An endogenous 13 residue peptide with rodent analgesia data and no human trial of any cognitive or pain endpoint. The human infusion studies that do exist measured gut motility: intravenous neurotensin increased colonic contraction duration to 76% in the ascending colon, and patients discharged a median 600 mL of bowel contents 20 minutes after the infusion stopped.

Neurotensin is an endogenous 13 residue peptide, annotated in UniProt P30990 at residues 151 to 163, cleaved from a precursor that also yields neuromedin N. It is a real and well-studied neuropeptide in animal neuroscience, with roles proposed in analgesia, thermoregulation, blood pressure and the pathophysiology of schizophrenia.

Mechanism: Proposed for the uses it is sold for, demonstrated for the ones it is not. Neurotensin acts at NTSR1 and NTSR2, G protein-coupled receptors, and at the sortilin-related NTSR3.

Regulatory history: Neurotensin is an endogenous peptide and is not a medicine. No neurotensin product or neurotensin receptor agonist is approved in any jurisdiction, and no interventional trial of either for pain is registered.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Neurotensin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.